Home > Dermatology > SPIN 2022 > New Treatment Options in Alopecia Areata > Alopecia areata: light at the end of the tunnel

Alopecia areata: light at the end of the tunnel

Presented By
Prof. Maryanne Senna , Harvard Medical School, MA, USA
Conference
SPIN 2022
Trial
Phase 3, BRAVE-AA1, BRAVE-AA2
Doi
https://doi.org/10.55788/f395271f
Alopecia areata (AA) has lacked effective treatment options for decades, and there is an unmet medical need for a reliable therapy in moderate-to-severe cases. With the approval of the first JAK inhibitor pending, there is a treatment for severe cases, “enfin”. AA is a chronic relapsing inflammatory disorder characterised by a non-scarring hair loss on the scalp and/or body. “Being able to do something for these patients has been life-altering for them,” said Prof. Maryanne Senna (Harvard Medical School, MA, USA) [1]. Hair loss has important implications regarding self-image, attractiveness, desirability, youthfulness, and self-esteem. “There is an insufficient acceptance that hair loss is an important medical problem,” she said. With a global prevalence of 2%, AA affects both sexes and has an initial onset typically before age 30. Around 10–20% of the patients will develop alopecia totalis. “In the US, until June 2022, no approved treatments for AA...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on